IPG Investment Advisors LLC Invests $838,000 in Thermo Fisher Scientific Inc. (NYSE:TMO)

IPG Investment Advisors LLC acquired a new position in Thermo Fisher Scientific Inc. (NYSE:TMOFree Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 1,655 shares of the medical research company’s stock, valued at approximately $838,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Halpern Financial Inc. grew its holdings in shares of Thermo Fisher Scientific by 307.7% during the 3rd quarter. Halpern Financial Inc. now owns 53 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 40 shares during the last quarter. Coppell Advisory Solutions LLC acquired a new stake in shares of Thermo Fisher Scientific during the second quarter worth $33,000. Live Oak Investment Partners bought a new position in Thermo Fisher Scientific during the fourth quarter worth $36,000. Tyler Stone Wealth Management bought a new position in Thermo Fisher Scientific during the second quarter worth $37,000. Finally, Indiana Trust & Investment Management CO bought a new position in shares of Thermo Fisher Scientific in the third quarter valued at $38,000. Institutional investors and hedge funds own 87.06% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on TMO shares. Raymond James raised their price objective on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a research note on Thursday, February 1st. KeyCorp lowered shares of Thermo Fisher Scientific from an “overweight” rating to a “sector weight” rating in a research note on Thursday, October 26th. Royal Bank of Canada increased their target price on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a report on Thursday, February 1st. HSBC began coverage on shares of Thermo Fisher Scientific in a report on Monday, December 18th. They issued a “buy” rating and a $610.00 target price for the company. Finally, Sanford C. Bernstein reiterated a “market perform” rating on shares of Thermo Fisher Scientific in a report on Monday, January 8th. Four analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $596.00.

Check Out Our Latest Analysis on TMO

Insider Activity

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the transaction, the chief executive officer now directly owns 49,155 shares of the company’s stock, valued at approximately $27,311,992.65. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Michael A. Boxer sold 14,566 shares of the business’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the transaction, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The disclosure for this sale can be found here. 0.32% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Performance

Shares of TMO traded down $2.68 during trading hours on Monday, hitting $548.07. The company’s stock had a trading volume of 535,619 shares, compared to its average volume of 1,928,942. The company has a market cap of $211.76 billion, a price-to-earnings ratio of 35.65, a PEG ratio of 2.31 and a beta of 0.80. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.75 and a quick ratio of 1.39. The business has a 50 day simple moving average of $533.33 and a two-hundred day simple moving average of $513.55. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $593.17.

Thermo Fisher Scientific (NYSE:TMOGet Free Report) last released its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, beating analysts’ consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The company had revenue of $10.89 billion during the quarter, compared to analyst estimates of $10.73 billion. During the same period last year, the business earned $5.40 earnings per share. Thermo Fisher Scientific’s revenue was down 4.9% compared to the same quarter last year. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 21.57 earnings per share for the current fiscal year.

Thermo Fisher Scientific declared that its Board of Directors has initiated a share buyback program on Tuesday, November 14th that permits the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization permits the medical research company to buy up to 2.2% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s board of directors believes its stock is undervalued.

Thermo Fisher Scientific Company Profile

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Read More

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.